126 results about "Transcriptional expression" patented technology

The invention discloses a plant stress-tolerance-associated protein TaDREB3A and a coding gene and application thereof. The protein provided by the invention is one of the following proteins: (a) a protein consisting of an amino acid sequence shown as a sequence 1 in a sequence list, and (b) a protein which is associated with plant stress tolerance and is derived from the sequence 1 by substituting and/or deleting and/or adding one or several amino acid residues for the amino acid sequence shown in the sequence 1. The TaDREB3A provided by the invention can express under the induction of drought, high salt, high temperature, low temperature, pathogenic bacteria, ABA (Abscisic Acid), ethylene, JA (Jasmonic Acid) and SA (Salicylic Acid), and can specifically regulate and control transcription expression of the gene containing a DRE/CRT (Dehydration-Responsive Element/C-Repeat) cis-element (core sequence: CCGAC); therefore, the drought resistance, the salt tolerance, the high temperature resistance and the resistance to the powdery mildew pathogen of the plant are improved. The TaDREB3A provided by the invention provides a base for artificially controlling the expression of genes related to the stress tolerance and the stress resistance, and is about to play an important role in cultivation of plants with enhanced stress tolerance and enhanced stress resistance.

Compared with human source tumor cell line models, PDX model tumors have the differentiated degree, morphological characteristics, structural characteristics and molecular characteristics closer to those of tumors of human bodies, so that an important in-vivo model is provided for biological study of tumors, searching of diagnostic markers and medicine screening. The invention provides a liver cancer PDX standardization model base which contains complete clinical information of patients with live cancer, pathologic types and grades, gene mutation and genetic transcription expression conditions; a patient primary tumor cell line corresponding to the liver cancer PDX model is established at the same time; comprehensive assessment which is nearly clinical is performed on the anti-liver cancer function of medicine on the cell level and the animal level.

The invention provides an aspergillus flavus pathogenic gene rgfC and an application thereof in screening of medicines used for preventing and treating aspergillus flavus contamination. The inventionalso discloses a method for screening and inhibiting pathogenicity of aspergillus flavus or screening medicines capable of preventing and treating aspergillus flavus contamination. More specifically,the method disclosed by the invention contains the following steps: adding a to-be-screened candidate into an aspergillus flavus culture system, detecting transcriptional expression level of an rgfC gene in aspergillus flavus, comparing with a control group which is not added with the candidate, and determining the candidate is a potential medicine capable of inhibiting the pathogenicity of aspergillus flavus or preventing and treating the aspergillus flavus contamination if the transcriptional expression level of the rgfC gene in a test group is lower than that of the control group statistically.

The present invention provides compounds and assays for the identification and validation of compounds for use in the treatment of muscular dystrophy (MD), or a form thereof, in which said compounds increase the post-transcriptional expression of a target gene (i.e., mIGF1, ITGA7, or UTRN).

The invention discloses a gluconobacter oxydans nonresistant marker gene knockout system, and belongs to the technical field of genetic engineering. According to the invention, through a homologous recombination technique, upp genes in G.o xydans are knocked out, so that a upp genetic deficient strain is obtained; a recombinant integrating plasmid containing a upp gene which can be subjected to good transcribed expression in G.o xydans and has a conditional lethal function, a resistance maker kanamycin resistant marker gene for the transformant selection of G.o xydans and an MCS polycloning site is built. The plasmid is applicable to the knockout and replacement of G.o xydans chromosome genes; compared with gene knockout implemented by taking a resistant marker gene as a selection marker, the system disclosed by the invention has the following two advantages: no resistant gene is introduced to a G.o xydans genome, so that a polar effect of the resistant gene on upstream and downstream genes is avoided; by using the knockout system, the multiple knockout and replacement of chromosome genes can be performed in a same strain.

The invention belongs to the field of plant genetic engineering and transgenic breeding and relates to a method for regulating and controlling growth of chrysanthemum petals through conversion of the CmTCP20 gene.The method includes the following steps that the CmTCP20 gene is cloned from florist's chrysanthemum 'ShenMa'; a plant expression vector of the CmTCP20 gene is constructed; the plant expression vector is transferred into chrysanthemum through an agrobacterium-mediated method, culturing is conducted, and a resistant plant is preliminarily obtained; the converted plant is subjected to PCR and quantitative RT-PCR detection to verify that the CmTCP20 endogenous gene is integrated to a genome DNA of the transgenic plant and subjected to transcription; the transgenic plant is subjected to phenotypic observation and statistic analysis, and it is found that compared with a plant not subjected to transgenosis, the petal growth amount of the transgenic plant is obviously increased.According to the method, the endogenous CmTCP20 transcription factors are converted and subjected to normal transcriptional expression, so that growth of the chrysanthemum petals is regulated and controlled, a novel and practical method is provided for improving ornamental quality of chrysanthemum through a genetic engineering technology, and the chrysanthemum biotechnology breeding process can be effectively promoted.

The invention discloses application of a 4N heterocyclic compound as an inhibitor for Th17 cell differentiation. In virtue of a luciferase activity screening system based on the activity of transcription factors, it is found that the 4N heterocyclic compound with a general formula as described in the specification has capability in inhibiting the key transcription factor ROR gamma t of Th17 cell differentiation and the inhibition capability EC50 is in a range of 0.2 to 1.5 [mu]M. In-vitro Th17 cell differentiation experiments prove that the 4N heterocyclic compound is capable of inhibiting Th17 differentiation, including substantially reducing the transcription expression of ROR gamma t, inhibiting the transcription expression of the effector molecules IL17A and IL17F of Th17 and obviously inhibiting the secretion level of IL17A cytokines in a culture. The 4N heterocyclic compound is expected to be developed into a drug used for treating autoimmune diseases, especially psoriasis, systematic lupus erythematosus, multiple sclerosis, rheumatoid arthritis, asthma or inflammatory intestinal diseases.

The invention discloses a method for testing the development process of silkworm embryos. The method specifically comprises the following steps of: (1), establishing a model expressing the incidence relation between the relative transcription expression quantity of the acetylcholine esterase type 1 (ace1) of a to-be-tested variety of the silkworm embryos and the development process of the embryos; (2), selecting at least one embryo from the to-be-tested silkworm embryos to use as a sample, testing the relative transcription expression quantity of the ace1 of the sample, and then contrasting with the model obtained in step (1) to determine the development process of the silkworm embryos according to the relative transcription expression quantity of the ace1 of the to-be-tested sample. The development stage of a whole graine can be accurately determined by the method through the test on the development process of a small quantity of silkworm embryos. Manual operation errors can be reduced, the test process is simplified, and a development process identification method is provided for molecular biology study of the silkworm embryos.

Provided are a plant stress tolerance related protein TaDREB4B and encoding gene and use thereof. The TaDREB4B protein has the amino acid sequence as shown in SEQ ID NO. 1, which can be expressed under induction by drought, high salt, high temperature, low temperature, pathogenic bacteria, ABA, ethylene, JA and SA, and can specially regulate the transcriptional expression of gene comprising the DRE/CRT cis element (core sequence: CCGAC), thereby enhancing the drought resistance, salt tolerance, high temperature tolerance and resistance to pathogenic bacteria of powdery mildew of plant.

The invention discloses a WRKY32 regulated YFT1 expression affected tomato fruit color and application of WRKY32 in tomato quality improvement. Specifically, the WRKY32 regulates the transcription expression of the YFT1 by combining a W-box (TTGAC, -784bp--780bp) motif (GTCTA, -1306bp--1302bp) in a YFT1 promoter region (defining the first nucleotide at the upstream of an initiation codon ATG of the YFT1 as -1bp). WRKY32 down-regulation expression tomatoes (WRKY32RNAi) are created through an RNAi technology, the fruit form and chemical phenotype of the WRKY32RNAi tomatoes are analyzed, and solid genetic evidences are provided for fruit ethylene release and signal transduction inhibition, carotenoid content reduction, chromosome development and fruit softening speed delay.

An in vitro method for the prognosis or prediction of response in patients with rheumatoid arthritis to treatment with agents recognising the B-lymphocyte CD20 membrane receptor. The method of the invention comprises an assay in a blood sample from these patients and measuring, before starting the treatment, the transcriptional expression level (mRNA) of at least one of the genes selected from the group: ARG1, CPD, TRAF1, C1QA, LRRN3, HLA-DQA1, NLK, TLR4, LOC89944, TOM1L1, BACH, NCALD, EIF2C2, NFIC, PCDHB7, FLJ32770, ARID3A, C14ORF9, CSNK1E, BCAS1, TEAD2, C6orfl45 and SNTA1; and the comparison of this expression level to the expression values previously obtained in patients who responded and who did not respond to the treatment.

The present invention relates to the use of split caspase proteins to determine whether or not promoters are coordinately active, whereby the transcriptional expression of incomplete portions of a caspase protein is controlled by different promoters and coordinate (not necessarily contemporaneous) promoter activity results in formation of an activated caspase protein and, consequently, apoptotic cell death. The present invention further provides for the use of an additional promoter element controlling expression of a “caspase neutralizing protein,” which, when present, inhibits the apoptotic effect of the assembled caspase subunits. Rescue of cells that actively transcribe the complementary caspase subunits indicates that all promoters of the system are coordinately active. The present invention, in non-limiting embodiments, may be used to selectively ablate cells in the context of cultures as well as intact organisms, and provides means of demonstrating coordinate activity of multiple promoters.

The present disclosure relates to polynucleotides having promoter activity and applications thereof in the production of amino acids. Specifically, the present disclosure relates to a polynucleotide having promoter activity, a transcription expression cassette containing the polynucleotide, a recombinant expression vector, a recombinant host cell, a method for enhancing expression of a target gene, a method for preparing a protein, and a method for producing an amino acid. The polynucleotide with the promoter activity is a mutant of the polynucleotide with the sequence as shown in SEQ ID NO: 9, compared with the polynucleotide with the sequence as shown in SEQ ID NO: 9, the promoter activity of the mutant is remarkably enhanced, stable and efficient expression of a target gene can be promoted, and then downstream products can be stably and efficiently produced.

The invention relates to application of oleanolic acid in preparation of drugs for treatment autoimmune diseases, and belongs to the technical field of biomedicine. The oleanolic acid can inhibit thefunction of the transcription factor ROR[gamma]t, inhibit the differentiation of Th17 cells, and inhibit the transcriptional expression of the target genes IL-17A and IL-17F of ROR[gamma]t at the RNAlevel, and inhibit IL-17A cytokines. The secretion inhibits the level of anti-dsDNA antibodies in the serum; the oleanolic acid of the present invention has an obvious Th17 cell activity inhibitory function, and provides a lead structure for the development of new drugs for the treatment of autoimmune diseases.

The invention provides a novel resistant gene of chloromycetin and application of the novel resistant gene of chloromycetin. The resistant gene has a sequence shown in SEQ ID No. 1 and is called aftera gene GMC; after tertiary sequencing of a genome, a drug-resistant gene known at present is not discovered on the genome, and then, through sequencing of RNA, it is discovered that GMC-encoded oxidoreductase has a very high transcription expression level in the presence of antibiotics. According to the novel resistant gene provided by the invention, a potential drug-resistant gene of the chloromycetin is discovered, help is provided for learning about a drug resisting mechanism of the chloromycetin and supplementing a drug resisting database, and a target point is provided for resisting drugresistance to the chloromycetin afterwards.

The invention relates to an influenza virus carried HCV nucleic acid test quality control product and a preparation method thereof; the quality control product is prepared from HCV conserved gene carried recombinant influenza virus through enlarged culture, inactivation and purification; the preparation method comprises the following steps: (1) constructing a plasmid which is used for rescuing influenza virus and is interpolated with HCV conserved gene in PR8 virus NS gene; (2) co-transfecting 293T cell to the constructed plasmid with plasmids which are respectively used for transcriptional expression of PR8 viruses PB2, PB1, PA, HA, NP, NA and M, so as to rescue and obtain HCV 5' UTR carried recombinant influenza virus; and (3) enlarged-culturing, inactivating and purifying the recombinant influenza virus so as to obtain the quality control product. The quality control product disclosed by the invention can be used for really simulating HCV pathogens and achieving all-around monitoring on HCV detection; and the quality control product is easy in large-scale preparation, low in cost, good in stability, easy in storage and transportation, and good in application prospect.